It is found in Pubmed that it was the first clinical academic paper on Nanoknife Ablation for large hepatocellular carcinoma published worldwide, marking that China was leading the world in the clinical application of Nanoknife therapy.
Fuda’s first academic paper on Nanoknife Ablation for large hepatocellular carcinoma published in an authoritative American journal.
Pubmed website
The paper was coauthored by minimally invasive interventional surgery group and central laboratory research group of Guangzhou Fuda Cancer Hospital. During the clinical research, minimally invasive interventional surgery group divided 14 liver cancer patients into two groups. The first group was composed of eight patients with large hepatocellular carcinoma, whose cancer were between 5.1cm and 11.5cm in diameter. The second group had 6 patients with medium hepatocellular carcinoma, whose cancer were between 3.0cm to 4.1cm in diameter. All patients from these two groups were treated by Nanoknife ablation.
The results showed that in the first group patients (with large hepatocellular carcinoma) had no major complications, and some had minor complications and their conditions were improved after symptomatic treatments. In the second group, the rate of patients having mild complications had no distinct difference with that of the first group, and the tumor ablation rate in this group is 66.6%.
Fuda's first academic paper on Nanoknife Ablation for large hepatocellular carcinoma included in an authoritative American journal.
Dr. Niu Lizhi, chief expert of minimally invasive interventional surgery group and president of Guangzhou Fuda Cancer Hospital, said, “This is Asia’s first clinical paper on IRE (Irreversible Electroporation) that has SCI impact factor. The research shows that applying Nanoknife ablation to treat large hepatocellular carcinoma is safe and its short-term effect is very good, especially it a better option for those with unresectable hepatocellular carcinoma.”
The paper also pointed out the morbidity of primary liver cancer in China and Southeast Asia was 5~8 times higher than that of the US and Europe. Though the preferred choice for treating primary liver cancer was radical resection, it was only suitable for less than 20% of patients.
Radio frequency ablation, microwave ablation and cryoablation are increasingly applied to treat unresectable liver cancer, yet they all have their limitations. Compared to traditional ablation techniques, Nanoknife ablation has distinct advantages in treating liver tumors close to important organs like hilar, vessel, bile duct, gallbladder etc. Nanoknife Ablation can be used clinically for unresectable liver tumors.
Fuda's first academic paper on Nanoknife Ablation for large hepatocellular carcinoma included in an authoritative American journal.
Fuda Cancer Hospital has brought in this advanced technique since China approved the clinical application of Nanoknife ablation in July, 2015. Fuda is the first hospital that started applying this technique in China, and also the one that has treated the most patients using Nanoknife ablation. The technique has very good effect especially in dealing with liver cancer and pancreatic cancer.
